Generation Bio (GBIO) announced it is leveraging its validated T cell-directed lipid nanoparticle to develop siRNA ...

Phillip Samayoa, chief strategy officer, will succeed Matthew Stanton as chief scientific officer. Stanton will remain with the company through mid-2025 and transition to its scientific advisory ...